Products for Research Use Only
RegisterLogin

PGN36

CAT: 0804-HY-146134-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-146134-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PGN36 is a selective cannabinoid CB2 receptor (CB2R) antagonist with Kis of 0.09 µM and >40 µM for CB2R and CB1R, respectively. PGN36 abolishes the increase in collagen type I gene expression by the inducer of bone activity. PGN36 is able to cross the blood-brain barrier. PGN36 can be used for the study of frontotemporal dementia (FTD) [1][2].
CAS Number
1564253-75-3
UNSPSC
12352005
Target
Cannabinoid Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/pgn36.html
Purity
99.74
Solubility
DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=[N+](C1=CC2=C(N(CC3=CC=CC=C3)N=C2OCC4CCCCC4)C=C1)[O-]
Molecular Formula
C21H23N3O3
Molecular Weight
365.43
References & Citations
[1]González-Naranjo P, et al. New cannabinoid receptor antagonists as pharmacological tool. Bioorg Med Chem. 2020 Oct 1;28 (19) :115672. |[2]Silva-Llanes I, et al. Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model. Brain Behav Immun. 2025 Mar 11;127:251-268.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CB2

Alternative Products

CatalogName
BA5226-5PGN36

Popular Products